

HLB GROUP

HUMAN LIFE BETTER





Human Life Better







HUMAN LIFE BETTER

**Dedicated to
technologies that prolong
and enrich lives**

HLB's journey, which began with Gyeongil Yacht in 1975 and Hyundai Lifeboats in 2000, has been defined by an unwavering commitment to developing life-saving technologies.

Today, HLB's dedication to saving lives has expanded into the diversified development of new drugs, with a primary focus on Best-in-Class anti-cancer therapeutics. We face challenges head-on, steadfast in our belief in the transformative power of life-saving technologies.

道行之而成

A path is made by walking on it

With over 50 years of history, HLB is paving the way toward a brighter future. We believe the path we create will lead to a better world, bringing happiness every step of the way.

BOARD CHAIRMAN'S MESSAGE

We are committed to growth through responsible governance, ethical practices, and active corporate citizenship.

HLB's journey, which began in 1975, reflects the essence of South Korea's manufacturing history.

From humble beginnings as a small lifeboat manufacturer on a remote seaside in Ulsan, we are now poised to take a leap as a global pharmaceutical and biotechnology company, marking the culmination of over a decade of dedicated efforts. We have grown but never rested, always rising stronger with every stumble and taking greater strides forward. Over the past 50 years, our relentless pursuit of progress has embedded the spirit of "overcoming and breaking through" into our very DNA.

Driven by ethical practices and an entrepreneurial spirit, we continually push our boundaries.

The journey to turn our shared dream into reality fills us with purpose and excitement.

Board Chairman **Jin Yang Gon**

HLB GROUP

With a focus on creating value for customers, fostering innovation, practicing responsible management, and fair competition, HLB continues to grow beyond its 50-year legacy toward a brighter future.

Driven by unwavering dedication to life and a passion for innovation, we strive to become a global leader, advancing humanity toward a happier and more fulfilling future.

Bio ·Pharmaceutical

HLB	HLB bioStep	Shinhwa Advance
HLB Healthcare Div.	HLB Panagene	BioSquare
HLB Life Science	HLB Cell	tiniko
HLB Life Science R&D	HLB bioCode	BioSquare
HLB Life Science Medicare Div.	HLB LifeCare	Elevar Therapeutics
HLB Life Science Medical Devices Div.	HLB NeuroTobe	Immunomic Therapeutics
HLB Pharmaceutical	HLB Genex	Verismo Therapeutics
HLB Therapeutics	HLB PEP	

Marine Business

HLB ENG	Penguin Ocean Leisure
HLB Ocean Tech	DAEHAE Ship Engineering
HLB Networks	Hyundai Ship Engineering
Hyundai Yachts	

Semiconductor ·Energy

HLB InnoVation	HLB Solution	HLB Energy
----------------	--------------	------------

Lifestyle

HLB Global	HLB F&B
HLB Life & Healthcare	Freshico

Investment

HLB Investment

Bio
Pharmaceutical

HLB	HLB bioStep	Shinhwa Advance
HLB Healthcare Div.	HLB Panagene	BioSquare
HLB Life Science	HLB Cell	tiniko
HLB Life Science R&D	HLB bioCode	BioSquare
HLB Life Science Medicare Div.	HLB LifeCare	Elevar Therapeutics
HLB Life Science Medical Devices Div.	HLB NeuroTobe	Immunomic Therapeutics
HLB Pharmaceutical	HLB Genex	Verismo Therapeutics
HLB Therapeutics	HLB PEP	

Since 1975

HLB

Core Business Areas

Development of new anti-cancer drugs

HLB has built its 'HLB Bio Eco System (HBS)' to support the entire process of new drug development and distribution for its pharmaceutical and biotech companies, fostering synergistic collaboration across the group.

The HLB Group strives to become South Korea's leading global pharmaceutical and biotech company, committed to improving and enriching human lives.

www.hlbkorea.com

hlb@hlb-group.com

+82 - 2 - 3453 - 1975

6F, The H Tower, 662, Nonhyeon-ro, Gangnam-gu, Seoul, Korea



Business Areas



Role of Affiliate

HLB Healthcare Div.

Manufacturing and distribution of medical devices and consumables

HLB Therapeutics

Development of the treatment of eye diseases and brain tumors, and distribution of drugs with cold chain logistics

HLB Cell

Development of cell therapy, hemostatic agents and tissue engineering products

HLB NeuroTobe

Development of treatments for intractable neurological disorder such as Parkinson's disease

Shinhwa Advance

Distribution of prescription drugs and consumables with nation-wide networks

Elevat Therapeutics

Global pharmaceuticals focusing on anticancer drug development

HLB Life Science

Development of anticancer drugs and manufacturing medical devices including disposable syringes, sales of IVD products

HLB bioStep

Korea No.1 non-clinical CRO in efficacy study

HLB bioCode

GLP-certified non-clinical CRO specializing in toxicology testing

HLB Genex

Business in Industrial and Special Enzyme, Biohealthcare Ingredient

BioSquare

Immunodiagnostic platform, QuantumPACK™

Immunomic Therapeutics

Development of DNA/RNA vaccine based on UNITE platform

HLB Pharmaceutical

Development of innovative drug products and pharmaceutical manufacturing, sales, and marketing

HLB Panagene

Production and distribution of molecular diagnostic product based on the synthetic nucleic acid material "PNA".

HLB LifeCare

Digital healthcare for chronic diseases. New medication of immunometabolic anticancer

HLB PEP

Pharma · Bio · Cosmetic Peptide, development of new peptide drugs

tiniko

Development of NiTi semi-final items and NiTirol products

Verismo Therapeutics

Development of the next generation of T-cell therapy (CAR-T)

Since 2008

HLB Healthcare Div.

Core Business Areas

In-vitro diagnostic kit, alcohol swab

Since its establishment in 2008, we have specialized in manufacturing quasi-drug products (alcohol swabs) that can disinfect skin or wound areas and disinfect medical devices.

Recently, it is contributing to the development of the bio-industry and human health-care by diversification of the business scope through investment in In-vitro-diagnostic medical devices (IVD) and FEMTECH-related fields.

www.hlbhc.com


hlbhc@hlbbio.co.kr

+82 - 44 - 862 - 9134

10-5, Myeonghaksandanseo-ro, Yeon-dong-myeon,
Sejong, Korea



Business Areas



In-vitro diagnosis and bio-healthcare services

We are developing innovative products and services that leverage nanoparticles, including graphene, carbon nanotubes, and magnetic beads, to advance disease prevention, diagnosis, and patient monitoring.




Femtech Supplies for women

We have been R&D and newly commercializing Femtech-related products under its slogan "women life better", along with various types of feminine cleansing products as well In-vitro medical devices such as pregnancy tester, ovulation tester, vaginitis test kit, and urethritis tests etc.

Main Products



Specimen Collection Swab



Specimen Transport Medium



Alcohol Swab



Alcohol Swab-s



Eol Swab



Sterile Lancet



Balancing Feminine Whipped Wash



Balancing Feminine Foaming Wash



Balancing Feminine Inner Care Gel



Balancing Feminine Tissue



Inner Saengak Pregnancy Tester



Inner Saengak Ovulation Tester



Inner Saengak Vaginitis Tester

Since 1988

HLB Life Science

Core Business Areas

Development of new anti-cancer drugs

HLB Life Science is a biopharmaceutical company developing innovative and -competitive anticancer drugs. By leveraging its in-house R&D capabilities and establishing a seamless collaboration network with global partners, HLB Life Science is growing into a specialized biopharmaceutical company.

www.hlb-ls.com


hlbls@hlb-ls.com

+82 - 2 - 2627 - 6700

5F, The H Tower, 662, Nonhyeon-ro, Gangnam-gu, Seoul, Korea




Business Areas




Rivoceranib

Rivoceranib is an oral anticancer drug that has therapeutic effects on many solid tumors. It is a targeted therapy which selectively inhibits Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). HLB-LS has exclusive right for development and sales of Rivoceranib in Korea, and partial rights in Japan and Europe.




Pyrotinib

Pyrotinib is a targeted anticancer drug that effectively inhibits the EGFR family (EGFR, HER2, HER4). It has demonstrated anticancer effects on HER2-positive advanced solid cancer. HLB-LS is planning more clinical trials to confirm the effectiveness of Pyrotinib on various solid tumors involving HER2.



G2M Inhibitor

G2M inhibitor interferes with the progression of G2 to M stage during the cell cycle (inhibiting the growth of cancer cells and inducing cell death). HLB-LS is conducting the non-clinical stage for the treatment of solid tumors.



CDK inhibitor

CDK (Cyclin-dependent kinase) is a key enzyme in a cell cycle. It inhibits Ser/Thr kinase that controls transcription by the activation of RNA polymerase II, thereby preventing the self-repair mechanism of cancer cells and inducing damage to cancer cells. HLB-LS is conducting screening research to identify druggable candidates



Cannabinoid-derived anticancer drug

Cannabinoids have anticancer properties, which can improve cancer therapy. This project determines the potential utility of cannabinoids in the treatment of cancer. HLB-LS is researching to discover new candidates for the treatment of solid tumors through the screening of various cannabinoid derivatives.

Since 2009

HLB Life Science Medicare Div.

Core Business Areas

**In-vitro diagnostic kit / Medical Healthcare
/ Consulting**

HLB Life Science Medicare Business Division delivers comprehensive plastic-based OEM/ODM manufacturing for finished medical devices, supported by rigorous quality management and deep expertise in In Vitro Diagnostics (IVD). To address evolving global regulations, we provide quality and regulatory consulting services aligned with international approval and licensing requirements, strengthening our partners' market competitiveness. Through strategic partnerships and the identification of high-potential domestic companies, we have built a strong distribution network across major hospitals. In parallel, we are expanding our B2C portfolio with IWANT, a premium infant care brand, creating differentiated brand value and enabling sustainable growth.

www.hlb-lsmc.com

info@hlb-ls.com


+82 - 31-658-8460

104, Yongmeori-gil, Gongdo-eup, Anseong-si,
Gyeonggi-do, Korea



Business Areas

OEM / ODM Manufacturing (In-Vitro Diagnostics, Medical Device , Cosmetics, Automotive Component)



Medical Healthcare



Collagen injectables



Wound Care Dressings



Nasal Aspirators



Since 2000

HLB Life Science Medical Devices Div.

Core Business Areas

Disposable syringes, Medical consumables

HLB Life Science Medicare Devices Div. specializes in manufacturing disposable syringes, disposable needles, filter syringes and a variety of other products with top-tier domestic manufacturing capabilities. By obtaining various certifications such as ISO 13485 and KGMP, the stability and effectiveness of the product have been recognized, and it is not only being supplied in large quantities to domestic large hospitals, university hospitals, small and medium-sized hospitals, and veterinary hospitals, but it has also received US FDA approval and is continuously exporting to overseas markets such as the US, Mongolia, and Vietnam.

www.hlb-ls.com

info@hlb-ls.com

+82 - 41 - 554 - 6181

20, Seongsimwon-gil, Seongnam-myeon, Dongnam-gu
Cheonan-si, Chungcheongnam-do, Korea



Business Areas



- Disposable syringe, Disposable needle
- Filter syringe, Tip cap of a syringe
- Insulin syringe, Pen needle, Infusion set
- Latex gloves, Nitrile gloves, Surgical gloves



Certification Status



Delivery Performance



Since 1998

HLB Pharmaceutical

Core Business Areas

Manufacturing & Sales of Pharmaceutical and Healthcare products, innovative R&D focused on the long-acting injectables and regenerative medicine.

HLB Pharmaceuticals focuses on pharmaceutical R&D, manufacturing, sales, and marketing. In addition, 'Quanchell' was launched as a joint healthcare product. At the R&D center, innovative products such as long-acting injectable microspheres and regenerative medicine including regenerative aesthetic dermal fillers are being developed. With its proprietary long-acting injectable platform, 'SMEB,' the company is developing long-acting injectable formulations of an apixaban-based thrombosis treatment and a GLP-1 analogue-based treatment for obesity and diabetes. Through these efforts, HLB Pharmaceutical is steadily advancing toward becoming a global leader in the biopharmaceutical industry.

www.hlbpharma.co.kr

hlbpharma@hlbpharma.co.kr

+82 - 31 - 557 - 0001

4F, The H Tower, 662, Nonhyeon-ro, Gangnam-gu, Seoul, Korea



Business Areas



IMD

- Improving patient convenience
- Development of long-acting injectable formulation using SMEB technology (Anticoagulant, Antiobesity, Antidiabetic etc.)



Generic Drugs

- CMO business (ETC/OTC)
- Generic formulation research



Consumer Healthcare

- Three healthcare brands: 'Quanchell' for joint health, 'Natia' for inner beauty, and 'HLB Pharmaceutical' for comprehensive health
- A wide range of products, from trendy superfoods to traditional health functional foods



Namyangju 1st plant



Hyangnam 2nd Plant

Since 2000

HLB Therapeutics

Core Business Areas

Cold chain business, treatment for eye disease, glioblastoma

HLB Therapeutics is unlocking the potential for 'Best-in-Class' drug development in areas such as ophthalmic diseases and brain tumors. Leveraging its specialized cold chain expertise, the company has been designated by the Korea Disease Control and Prevention Agency as a provider for COVID-19 vaccine storage and distribution. We are at the forefront of ensuring the stable distribution of vaccines and a wide range of pharmaceuticals.

www.hlbtherapeutics.co.kr

contact-hlb@hlbtherapeutics.com


+82 - 31 - 786 - 7800

3F, The H Tower, 662, Nonhyeon-ro, Gangnam-gu, Seoul, Korea



Business Areas

New drug development




Treatments for ocular diseases

RGN-259 is an ophthalmic solution with Thymosin $\beta 4$ as its active ingredient, exhibiting wound healing and anti-inflammatory effects. It is currently under development by the U.S.-based joint venture, ReGenTree, LLC. The treatment for Dry Eye Disease (DED) is suitable for multifactorial diseases related to tear deficiency or excessive tear evaporation and is under phase 3 study. The treatment for Neurotrophic Keratitis (NK) is appropriate for degenerative corneal diseases with corneal epithelial damage, ulcers, and perforations. It has been designated as an orphan drug by the FDA, with phase 3 clinical trials ongoing in the U.S and Europe.

Glioblastoma multiforme (GBM) treatment

Glioblastoma multiforme (GBM) is a malignant brain tumor that originates from cells present in the brain tissue. OKN-007 has effects that enhance the tumor microenvironment, inhibiting the immunosuppressive effects of cancer treatments, reducing hypoxia-induced occurrences, and suppressing the formation of new blood vessels by cancer cells. Additionally, it temporarily opens the blood-brain barrier (BBB) to improve drug penetration. It has been designated as an orphan drug by the FDA, and the U.S.-based corporation, Oblato, Inc., is currently conducting phase 2 trials for recurrent GBM and an investigator-initiated trial for a newly diagnosed GBM.

Cold Chain Business



The cold chain business refers to the distribution of pharmaceuticals that require low-temperature handling, maintaining a specific temperature throughout their transit. Especially in 2022, with the strengthening of pharmaceutical distribution and sales management, the distribution of biological medicines through cold chain infrastructure has become mandatory. Equipped with a nationwide cold chain system in place, we were selected as the sole distributor of the official COVID-19 vaccines from 2023 to 2025. Additionally, we are engaged in the distribution of blockbuster vaccines for influenza, shingles, pneumococcus, cervical cancer, and M-POX.

Since 2012

HLB bioStep

Core Business Areas

Non-clinical CRO, Bio-infra

HLB bioStep is a leading non-clinical CRO in Korea, providing efficacy, PK/TK, toxicology, and pathology services for drug and medical device development. Combining advanced imaging with veterinary expertise, we support the full early-development cycle and deliver one-stop Bio-infra.

www.hlbbiostep.com

ask@hlbbiostep.com

+82 - 833 - 8899

38 Academy-ro 79beon-gil, Yeonsu-gu, Incheon, Korea



Business Areas



Non-clinical CRO

Leveraging veterinary expertise, we conduct comprehensive non-clinical studies for new drug candidates and medical devices, including efficacy, pharmacokinetics (PK)/toxicokinetics (TK), toxicology (safety), and pathology services.

Non-clinical CRO Service Areas

- Target & Candidate Efficacy Evaluation
 - In vivo efficacy & disease models
- GLP Toxicology
- Bioanalysis
 - PK/TK, exposure-response, Biomarkers
- Pathology Services
 - Histopathology & Integrated Tissue Analysis
- IND-enabling & Hybrid Translational Consulting
 - Preclinical → Clinical, Animal ↔ NAMs ↔ Clinic



Bio-infra (lab consulting/build-out)

One-stop consulting, design, construction, maintenance, and equipment supply for large-scale laboratories—animal testing, alternative-to-animal, LMO, GLP, and GMP.

Bio-infra Business Area

- LAB consulting
- Design
- Construction (General contracting)
- T.A.B
- Fumigation
- Maintenance
- Equipment
- Validation



Biotech Venture Investment (Open Innovation)

Strategic investments and collaborations across therapeutics (pharmaceuticals)/vaccines, diagnostics/medical devices, and veterinary medicines.

Key Success Cases



- Next Biomedical
- : Hemostatic Systems for Endoscopy received U.S. FDA clearance.



- ICM
- : Osteoarthritis treatment obtained U.S.IND clearance.

Since 2001

HLB Panagene

Core Business Areas

**Diagnostics (Molecular diagnostics, Nucleic acid extraction, Spatial proteomics),
Materials (PNA/DNA Supply, AOC new drug)**

Since its establishment in 2001, HLB Panagene has been at the forefront of research and development in the field of PNA, a synthetic nucleic acid material, and PNA-mediated molecular diagnostic products. We produce and supply high-quality customized PNA and other types of nucleic acids. Leveraging our proprietary technology, we have successfully ventured into diverse markets including companion diagnostics for cancer, infectious disease testing, and nucleic acid extraction. HLB Panagene has expanded its business scope into spatial proteomics analysis (including AI analysis), AOC new drugs, thereby providing total service related to diagnostics and materials.

www.hlbpanagene.com


info@hlbpanagene.com

+82 - 42 - 861 - 9295

54, Techno 10-ro, Yuseong-gu, Daejeon, Korea




Business Areas



PNA / DNA Materials

Globally supplies PNA (peptide nucleic acid) and DNA using own mass production technology and expectational capacity for customized production.




Molecular Diagnostics & Nucleic Acid Extraction

Develop, produce, and distribute products designed for testing genetic mutations in cancer patients, along with solutions for detecting infectious pathogens.




Spatial Proteomics & AI Analysis

Provides analysis services including cell type, distribution, state and interactions, etc. by identifying > 40 types of proteins and their spatial information together at the cell level resolution.



Nucleic Acids

Supply various nucleic acids including Phosphorothioate (PS), Locked nucleic acid (LNA), etc.



AOC (Antibody Oligonucleotide Conjugate)

Research and develop a new modality - an antibody conjugated to PNA-based oligonucleotides



PNA-based Molecular Diagnostics

PANAMutyper™ R - EGFR, EGFR V2
OncoTector™ - KRAS, ROS1, BRAF
PANARealTyper™ - STD, HPV, CRE



Nucleic Acid Extraction

Automated instruments and kits (PANAMAX™) used to extract nucleic acids in various types of samples including FFPE, Blood, Bacteria, Virus, etc.



Hyperion XT / CyTOF XT

Provides multiplex single cell detection and quantitative analysis in tissue slides and liquid samples to discover biomarkers, mechanisms, and apply in companion diagnostics.



Business Areas

Core Business Areas

Materials and finished products for biopharmaceuticals /medical devices



Starting as Asia's first umbilical cord blood bank with a stem cell research institute, the company became independent in 2009, focusing on the development of cell therapies and advanced tissueengineered products. With a deep understanding of the fundamental unit of life, the "cell," we aim to provide regenerative medicine solutions for treating intractable diseases.



Human extracellular matrix, Hutrigel®


Hutrigel® is a human extracellular matrix (ECM) that serve as support for tissues and organs, which is manufactured by using a proprietary cell culture, isolation/separation and formulation technology. Hutrigel® is a platform technology because it can be used for multiple purposes, such as stem cell /organoid culture materials, tissue augmentation/regeneration or aesthetic medical devices.

Hutrigel® (Human ECM Platform) Pipeline (More pipelines in development)



Hemostat, BleeFix®

A powder-type hemostat with excellent biocompatibility and superior hemostatic properties. It can be used not only for various external hemorrhages but also during surgeries .



Bio-artificial liver, LifeLiver®

LifeLiver® is a cell therapy for extending the golden time for patients with acute liver failure who are waiting for a liver transplant.



Supplying primary human hepatocytes, LifeHepa®

For the first time among domestic companies, we provide a service that supplies primary hepatocytes from human livers for drug metabolism and pharmacokinetic testing of new

Since 2009

HLB bioCode

Core Business Areas

GLP Toxicology Studies , Non-clinical CRO

HLB bioCode Co., Ltd. is a GLP (Good Laboratory Practice) non-clinical toxicity testing institute certified by the Ministry of Food and Drug Safety, the Ministry of Environment, and the Animal and Plant Quarantine Agency.

We conduct toxicity tests in accordance with international testing guidelines that meet domestic and international standards, and the test data generated by our company are recognized as regulatory submission data not only in Korea but also in Asia, Europe, the United States, and other regions.

www.hlbbiocode.com

bd@hlbbiocode.com

+82 - 31 - 278 - 5361

155, Maeyoung-ro, Yeongtong-gu, Suwon-si,
Gyeonggi-do, Korea



Business Areas

Non-clinical GLP Toxicology Studies



Certification Status



Major Clients





Since 2021

HLB LifeCare





Core Business Areas

AI Chronic Prediction, Medical Device Personalized Functional Foods, Biopharma

HLB LifeCare provides comprehensive healthcare solutions for the prevention and management of diseases.

HLB LifeCare offers integrated solutions for the prevention, diagnosis, and treatment of chronic diseases and cancer, leveraging AI-powered digital healthcare technologies and cohort data from leading medical institutions.

Business Areas



AI Chronic Prediction

Prediction and Management of Chronic Diseases based on AI
HLB Lifecare provides an AI-based, hyper-personalized platform for the prediction and management of diabetes and chronic diseases, leveraging cohort data from a large network of leading medical institutions.

Medical Device

Development of Data-Driven, Personalized Medical Devices for Prevention, Diagnosis, and Management Using Various Medical Devices HLB Lifecare develops data-driven, personalized medical devices for the prevention, diagnosis, and management of diabetes and its complications, starting from real-time glucose monitoring with continuous glucose monitoring (CGM) systems, and expanding to various diagnostic devices related to diabetes management and complications.

Personalized Functional Foods

HLB Lifecare is developing personalized functional foods by researching and creating tailored ingredients and products for the prevention, treatment, and management of diabetes and chronic diseases.

Biopharma

HLB Lifecare is working to overcome the limitations of third-generation anticancer drugs and immunotherapy through Deep-tech TIPS government projects.

www.hlbifecare.co.kr

hlblifecare@hlblifecare.com

+82 - 2 - 555 - 0128

1F, 8, Yeoksam-ro 38-gil, Gangnam-gu, Seoul,
Korea

Major Partners



Since 2021

HLB NeuroTobe

Core Business Areas

New Drug Development for Neurological Disorders

HLB NeuroTobe, a startup from Korea Advanced Institute of Science and Technology (KAIST), is dedicated to developing innovative drugs for global neurological disorders. The company is focused on creating treatments for intractable neurological conditions, including the three major movement disorders: Dystonia, Parkinson's disease, and Essential tremor. These conditions still lack treatments targeting their root causes, leaving significant unmet medical needs for both patients and physicians. HLB NeuroTobe aims to become one of the top 10 global companies in the neurodegenerative disease treatment field by addressing the root causes of these conditions.

www.hlbneurotobe.com

hlbneurotobe@hlbneurotobe.com


+82 - 42 - 862 - 9745

193, munji-ro, Yuseong-gu Daejeon, Korea




Business Areas

Pipelines



Dystonia Treatment : NT-1

Dystonia is a disorder where muscle contractions or spasms occur locally or throughout the body involuntarily, often triggered by excessive stress. NT-1 is a small molecule drug that effectively inhibits the excessive release of serotonin (which excites cerebellar neurons), identified as a cause of dystonia, by blocking 5HT-2A receptors.



Parkinson's Disease Treatment : NT-3

Parkinson's disease is caused by the loss of dopamine neurons in the substantia nigra of the midbrain, leading to symptoms such as muscle rigidity, tremors, and gait abnormalities. HLB NeuroTobe has identified that a "Rebound Excitatory Signal" occurs in the thalamus due to a decrease in dopamine signaling, which is counteracted by inhibitory neurotransmitter GABA. The company has determined that this abnormal signal is a direct cause of Parkinson's disease and is developing a gene therapy called NT-3, which effectively inhibits this signal by targeting CaV3.1.

Major Partners



Since 2000

HLB Genex

Core Business Areas

Industrial/Specialty Enzymes & Bio-Healthcare ingredients

Founded in 2000 as a spin-off from the Korea Research Institute of Bioscience and Biotechnology(KRIBB), HLB Genex has been developed and supplied customized enzymes and bio-healthcare ingredients, essential for various industries including food, cosmetics, pharmaceuticals, and semiconductors, by utilizing proprietary customized protein development and precision fermentation technologies.

www.hlbgenex.com

info@hlbgenex.com

+82 - 42 - 862 - 4483

65 Techno 1-ro, Yuseong-gu, Daejeon, Korea



Business Areas

Industrial & Specialty Enzymes

Customized enzymes for various sectors, including semiconductors, food, diagnostics, and pharmaceuticals



Bio-Healthcare ingredients

Functional ingredients used in the pharmaceutical, nutraceutical, and cosmetic industries



Major Products

Catalase (Katalase AK 400L, S 350L)

Antioxidant enzyme for hydrogen peroxide decomposition into oxygen and water. Catalase is used for the eco-friendly removal of hydrogen peroxide in semiconductor and textile industries.

Lactase (Lactazyme-B)

Bioconversion enzyme for the production of galacto-oligosaccharide(GOS), a prebiotic similar to components found in human breast milk. GOS is used in premium infant formula and functional dairy products.

Phytosphingosine (NPY)

A precursor of natural ceramide, which is a functional cosmetic ingredient with antimicrobial and anti-inflammatory effects, and is excellent for maintaining and restoring the skin barrier.

Vitamin K2 (MediQ7)

High-purity natural vitamin K2(menaquinone-7) produced through microbial fermentation. Vitamin K2 supports bone and cardiovascular health.

SOD (Superoxide Dismutase)

Antioxidant enzyme produced through microbial fermentation. SOD has various clinical benefits including anti-inflammatory effects, eye health, gut health, and infertility improvement.

Nattokinase

Thrombolytic enzyme, a functional food ingredient that improves and prevents cardiovascular diseases by inhibiting thrombus formation and lowering blood pressure.

Since 2000

HLB PEP



Business Areas

Peptide Pharmaceutical Material (API) manufacturing

APIs	Indications	Milestone		
		Under development	DMF Registered	Commercialized
Leuprorelin DMF, Ph. Eur, USP (FDA #25878)	Prostate cancer, Precocious puberty, For IVF			
Desmopressin DMF, Ph. Eur, USP	Nocturnal enuresis			
Ganirelix DMF, USP (FDA #040573)	Sterility			
Vasopressin DMF, Scheduled for US FDA DMF submission in 3Q 2026	Antidiuretic Hormone(ADH)			
Tatirelin(Oral drug) Under development	Spinocerebellar Degeneration(SCD)			DMF scheduled for PMDA submission in 4Q 2026
Semaglutide Under development	Type 2 Diabetes, Chronic weight management			

In the peptide field, we were the first in Korea to obtain GMP peptide approval and self-produce it, and we succeeded in localizing Active pharmaceutical materials that had previously been entirely dependent on imports, and we are stably supplying high-quality materials.

Peptide Biomaterials CDMO

JangSeong 1st GMP	cGMP / EU-GMP / PMDA ->Registration & Certification in progress	Osong 2nd GMP	Raw material	Efficacy
	✓Global CDMO Expansion ✓API Global Export Manufacturing Facility Batch Info Annual Capacity GMP Plant 1 (Jangseong) 500 g / Batch ~ 50 kg GMP Plant 2 (Osong) 1.5 kg / Batch ~ 150 kg Non-GMP Center (Gwangju) 1 kg / Batch ~ 50 kg Total ~ 250 kg		Curcumin Peptide	Anti-Wrinkle, Acne, Moisturizing, Antioxidant
- Korea's 1st Peptide GMP Plant - EMA QP Declaration Authorized (DS Part Clinical Trial Supplies)		- Korea's Leading Peptide-Dedicated GMP - EUS FDA Pre-approval Inspection (PAI) Completed - EMA QP Declaration Authorized - LIMS(Lab Info. Management System) Implemented	Herbal Natural Organic Acid Peptide	Anti-Wrinkle, Antioxidant
			Seaweed Peptides	Whitening, Antioxidant

Peptide new drug pipeline Development of Peptide Cosmetic Raw Material

Based on the peptide synthesis know-how accumulated over many years, we are developing human-friendly, high-functional cosmetic raw materials that pursue natural beauty by utilizing natural materials.

Candidate	Indications	Milestone			
		Discovery	Pre-Clinical(Efficacy, Toxicity)	Phase 1	Phase 2 / 3
AGM-217	Metabolic Therapies for Diabetes and Obesity				
AGM-290	Broad-spectrum Antibacterials for MDR Infections				
AGM-330	Selective Targeted Cancer Therapies				

www.hlbpep.co.kr

order@hlbpep.co.kr

+82 - 62 - 714 - 1166

206, Pilot Plant, Gwangju Technopark,
Cheomdan Gwagi-ro 333, Buk-gu, GwangJu, Korea

Since 1991

Shinhwa Advance

Core Business Areas

Distribution and sale of prescription drugs

Founded in 1991, Shinhwa Advance is specialized in the distribution of prescription drugs with leading domestic and international pharmaceutical companies such as Yuhan Corporation as clients. It is continuously expanding its product portfolio and is in the process of establishing business partnerships with major hospitals including university hospitals and general hospitals.



Business Areas

Drug wholesale

Distribution of OTC and ETC drugs to drug wholesalers and large hospitals through direct transactions with pharmaceutical companies

Pharmacy

Distribution of OTC and ETC drugs to pharmacies near hospitals through direct transactions with pharmaceutical companies

Medical supplies and consumables

Procurement and logistics services for medical supplies, surgical instruments, and consumables used in hospitals

Major Clients



www.shinhwaadvance.kr

shinhwa@sh-adv.co.kr

+82-2-834-7971~3

10, Seonyu-ro 9-gil, Yeongdeungpo-gu, Seoul,
Korea (215,216)

Since 2017

BioSquare Inc.


Core Business Areas

Immune Diagnostic Platform

BioSquare is a healthcare platform company providing a total solution for disease prevention, diagnosis and management as a platform creator by bringing in QuantumPACK™ technology. We also provide an open platform based on nanomaterial synthesis technology, optical analysis technology, IT configuration, and experimental automation technology.




Business Areas



Development/Commercialization of nano-material (Quantum Dot)-based IVD



**Optical analysis technology/
IT Configuration**



Development/Commercialization of nano-material (Quantum Dot)-based IVD Instrument

Major Products



QDITS Basic



QDITS Basic
Autofeeder



QDITS Smart



QDITS Mini



Influenza (A+B)



RSV
(FDA Listed)



COVID-19
(For Clinicians)



Strep A
(FDA Listed)



COVID-19
(Home Test)

www.bio-square.com

sales@bio-square.com

+82-31-8043-5293

15, Samsung 1-ro, 4-gil, Hwaseong-si,
Gyeonggi-do, Korea




Business Areas

Core Business Areas

TiNi Super Elastic Biomaterials

- Manufacturing of TiNi Super Elastic Biomaterials
- Manufacturing of implantable medical devices
- Manufacture of military and robot parts
- Manufacturing of TiNi Medical Porous Bodies
- Ppuri industry certified company
(Foundation process technology certified company)



Major Products

tiniko TiNi Superelastic Biomaterials of Korea
The only company in Korea specializing in ultra-precision medical materials based on nitinol.

	SpineLant®	BoneLant®	SpongyLant®	MeshLant	NoNNos®
Medical Use					
Industrial Use	Nitinol Ingot	Nitinol Wire	Nitinol Sheet	Nitinol Bar	Heat Shrink Ring

Since 2005

Elevar Therapeutics

Core Business Areas

R&D of anti-cancer therapeutics

Elevar Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing and commercializing innovative oncology medicines for complex and under-treated diseases. Elevar's lead pipeline programs include rivoceranib and liralufugratinib. The NDA for rivoceranib in combination with camrelizumab as a first-line treatment for unresectable hepatocellular carcinoma (HCC) is currently under review by the U.S. FDA. In addition, an NDA submission for liralufugratinib is planned in 2026 for the second-line treatment of cholangiocarcinoma patients with FGFR2 fusions/rearrangements. Phase 2 development of liralufugratinib is also ongoing for a tumor-agnostic approach in solid tumor patients with FGFR2 fusions/rearrangements.

www.elevartherapeutics.com

info@elevartherapeutics.com

+1-801-303-7440

One Bridge Plaza North Suite 850
Fort Lee, NJ 07024 U.S.A



Business Areas

PIPELINE

Molecule	Therapeutic Area	Indication	Phase 1b	Phase 2	Phase 3	NDA Filed	Approved
Rivoceranib + Camrelizumab	Oncology	Unresectable Hepatocellular Carcinoma (uHCC) 1L (Hengrui Collaboration)*					
Rivoceranib	Oncology	Adenoid Cystic Carcinoma (ACC)* Recurrent or Metastatic					
Rivoceranib	Oncology	Gastric Cancer Monotherapy 3L/4L					
Liralufugratinib	Oncology	FGFR2-altered cholangiocarcinoma, 2L*					
Liralufugratinib	Oncology	Solid tumors with FGFR2 alterations					

*Orphan Drug Designation

Rivoceranib and Camrelizumab

Rivoceranib is a VEGFR-2 inhibitor currently being studied as monotherapy and in combination with chemotherapy and immunotherapy in various solid tumor indications. Results from the Phase 3 CARES-310 study of Camrelizumab plus Rivoceranib in 1L unresectable HCC showed meaningful improvements to safety and efficacy, including median OS of 23.8 months. Elevar holds global rights (excluding China and South Korea) to rivoceranib, and has partnered with HLB-LS for its development and commercialization. Elevar also holds a right to commercialize camrelizumab in combination with rivoceranib for uHCC worldwide excluding Greater China and South Korea.

Liralufugratinib

Liralufugratinib is a highly selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) being developed for patients with FGFR2 altered cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. Elevar Therapeutics holds exclusive global rights for liralufugratinib, including all further development and global commercialization activities. Liralufugratinib was granted breakthrough therapy designation for CCA, orphan drug designation, and a pediatric study waiver by the FDA.

Since 2005

Immunomic Therapeutics


Core Business Areas

Research and development of immuno-cancer drugs

Founded in 2005, Immunomic Therapeutics Inc. (ITI) develops immune cell therapies and vaccines. Its UNITE platform has broad applications when used in combination with cell therapies and DNA/RNA vaccines. ITI is currently developing various immune therapies for cancers and allergies.



Business Areas



UNITE Platform (Universal Intracellular Targeted Expression)

UNITE is a next generation immunotherapy platform that works by fusing lysosome-associated protein with target antigens, enhancing antigen presentation and consequently activating the immune response in killer T-cells, memory T-cells and B-cells. It has the potential to be applied to treat various diseases including cancer and allergies.


GBM

- Autologous DC vaccine - ITI-1000
- Allogenic pDNA vaccine - ITI-1001


Other oncology therapy

- Head and neck cancer vaccine - ITI-2000
- MCC(Merkel cell) vaccine - ITI-3000
- TNBC vaccine - ITI-5000
- Obesity treatment - ITI-8000


Allergy therapy

- Japanese Red Cedar Allergy- ITI-9001
- Animal Allergy Therapy

Multiple Pipelines Including a Glioblastoma Therapy

Immunomic Therapeutics currently has multiple pipelines focused on treatments for cancer, allergies, and infectious diseases.

Clinical studies for ITI-1001, a naïve GBM therapy are ongoing. In addition, ITI-5000, a TNBC therapy, has received IND clearance in the U.S. and plans to commence clinical trials shortly, and ITI-9001, a treatment for Japanese Red Cedar allergy, is preparing to enter clinical trials in Japan.

www.immunomix.com

info@immunomix.com

+1-301-968-3501

15010 Broschart Road Suite 250 Rockville, MD, USA

Since 2020

Verismo Therapeutics

Core Business Areas

Next Generation CAR-T R&D

Verismo Therapeutics is a clinical-stage company established in 2020 by the team behind Kymriah, the world's first approved CAR-T (Chimeric Antigen Receptor-T) cell therapy. Verismo aims to overcome the limitations of existing CAR-T therapies in treating solid tumors and provide solutions for patients with relapsed or refractory blood cancers through its next-generation KIR-CAR platform technology.

www.verismotherapeutics.com


info@verismotherapeutics.com

+1-267-244-8115

3675 Market Street, Suite 200 Philadelphia, PA, USA



Business Areas



KIR-CAR platform

CAR-T therapy involves genetic engineering of patients' T-cells to precisely target and attack cancer and other diseased cells.

Verismo's dual-chain KIR-CAR structure, inspired by Killer Immunoglobulin-like Receptors (KIR) found in Natural Killer (NK) cells, is designed to activate only upon engagement with the target antigen, and is thereby expected to avoid T-cell exhaustion which may lead to a more durable response compared to conventional single-chain CAR-T therapies.



Multiple pipelines in oncology

SynKIR-110, Verismo's lead pipeline for patients with Ovarian Cancer, Cholangiocarcinoma, and Mesothelioma, is currently under phase 1 study in the US. SynKIR-310, Verismo's second pipeline, is under phase 1 study in the US for the treatment of CARnaïve and post-CAR relapsed patients with B-cell Non-Hodgkin Lymphoma.

Marine Business

HLB ENG

HLB Ocean Tech

HLB Networks

Hyundai Yachts

Penguin Ocean Leisure

DAEHAE Ship Engineering

Hyundai Ship Engineering

Since 1975

HLB ENG

Core Business Areas

Lifeboat, Special ship, GRP and GRE pipes

For over 50 years, HLB ENG has built more than 8,000 vessels, including lifeboats made from advanced composite materials. Through the production of high-quality GRP and GRE pipes and the development of eco-friendly propulsion and autonomous surface vessel technologies, we are leading innovation in maritime safety and a sustainable future.



Business Areas

Shipbuilding Business

Totally enclosed lifeboat



Free-fall lifeboat



Special ship



Government vessel



Materials Business

Onshore Pipe



Offshore Pipe



Marine Pipe



Marine Pipe



Major Clients



www.hlb-eng.com

techsales@hlb-eng.com

+82-52-240-3500

216-53, Dangwol-ro, Onsan-eup, Ulju-gun, Ulsan, Korea

Since 1992

HLB Ocean Tech

Core Business Areas

Manufacturing of shipbuilding equipment

HLB Ocean Tech has been running for the vision and passion as to be a 'World No. 1 Creator for the Marine Lifting Solution', with more than 30 years in technological experience.

HLB Ocean Tech will be responsible for the safety of all of people at sea and lead a lifting & handling product in all fields in marine & offshore industry, special ships, and commercial ships with creative, reliable, convenient and durable products for the solution in maritime situation for the customer satisfaction.

www.hlboceantech.com

marketing@hlboceantech.com

+82-55-720-1021/22/02

135-56, Jinsan-daero, Jinyeong-eup,
Gimhae-si, Gyeongsangnam-do, Korea



Business Areas


Special Ship Equipment (Navy & Coast Guard & Submarine)




Offshore Equipment (FPSO, FLNG, Windfarm, Research Vessel)



Merchant Ship Equipment (Container, Bulk, LNG, Carrier, Passenger Vessel)



Major Clients



Since 2009

HLB Networks

Core Business Areas

Marine Safety Solution

Building upon years of accumulated expertise since its establishment, our company leverages a global network spanning 40 countries and 85 locations to offer comprehensive and specialized ship maintenance solutions. We provide services such as inspection and repair of vessels, training for overseas agents, and sales of vessel supplies and parts. Positioning ourselves as a comprehensive service provider dedicated to maritime safety.



Business Areas



Services

Offers annual and 5-year precision inspection and repair services to ensure the safe operation and maintenance of lifeboats.



Training and Education

Implements and offers service provider training to enable the agents to conduct inspections and repairs of lifeboats and davit in accordance with the regulation MSC.402(96).



Sales

Supplies and sells lifeboat parts, marine engines, and lifeboat release hooks.

www.hlbnetworks.com

service@hdbboat.com

+82-52-240-3529

216-53, Dangwol-Ro, Onsan-Eup, Ulsu-Gun, Ulsan, Korea

Hyundai Yachts

Since 2008

Hyundai Yachts

Core Business Areas

Marine Leisure Business Solutions

Hyundai Yachts, a pioneer in Korea's yacht industry, offers comprehensive solutions for the marine leisure industry. We are committed to expanding yachting culture through the sale of world-renowned luxury yachts, premium chartering services, marine training, and marina consulting. Our mission is to set new trends in marine leisure and being a reliable partner in fulfilling your yachting dreams and delivering a distinctive experience.

www.hdyachts.com

info@hdyachts.com

+82-2-561-1975

THE RIVER 1F, 2085-96, Olympic-daero, Yongsan-gu, Seoul, Korea



Business Areas

Imports and Sales

FERRETTI GROUP (Italy), SWAN (Finland), PRESTIGE (France), BAVARIA (Germany), EXCESS (France)



Design and Manufacturing



Yacht Charter Services

The River



Storage · Maintenance

Yacht · Marina Business Consulting

Maritime Leisure & Yacht Operation Training

Since 2014

Penguin Ocean Leisure

Core Business Areas

Comprehensive Marine Travel and Leisure Platform

Penguin Ocean Leisure is a comprehensive marine leisure company specializing in the sales and distribution of boats and fishing vessels for marine leisure and fishing activities. We also develop our own range of leisure boats, including the semi-submersible motorboat "Penguin" and the inland sightseeing boat "Circle Boat." In addition, we offer unique marine underwater tourism services such as sea walking and freediving, serving as a bridge connecting people with the ocean. By promoting safe and enjoyable marine leisure and fishing experiences for everyone, we continue to lead the way in shaping the future of marine culture.

www.tourwithpenguin.com

inquiry@penguinol.com

+82-2-3443-1458

272-12 Dangwol-ro, Onsan-eup, Ulsan-si, Korea



Business Areas

Lei-Fishing Division



Marine Leisure and Fishing Business

- Sales of fishing boats
- Building Database of Fishing boats and their owners



Marine Leisure Content Division



Marine Leisure Platform Management

- Development and consulting of customized content for local governments and private businesses
- Operation of marine leisure services and platforms

Operational Content




E-commerce Division



E-commerce Operation Services

- Customized product solutions and exclusive benefits for HLB employees
- Online shopping mall management



Marine Leisure Equipment

- Developed the world's first leisure semi-submersible, the 'Penguin'
- Pioneered the development of the eco-friendly hydrogen fuel cell 'Donut Boat'
- Innovated the 'Circle Boat' an inland watercraft featuring autonomous driving technology.

Since 2017

DAEHAE Ship Engineering

Core Business Areas

Ship Design and Engineering

Daehae Ship Engineering offers comprehensive ship design and engineering solutions with extensive experience across various types of vessels. We cover the entire process, from basic design, structural analysis, and 3D modeling to supervision, and construction, for a wide range of vessels. With our expertise in designing and building the country's largest HDPE ship, we aim to lead in the design and construction of HDPE and eco-friendly ships.




Business Areas

Conceptual and
Production design



Structural and
Fluid analysis



Technical consulting
and Supervision



3D scanning and
Reverse engineering



Certification Status



Major Clients



www.daehae.com

shipdh@daehae.com

+82-70 - 4416 - 0801

Rm.1012-1014, 99, Centum dong-ro, Haeundae-gu,
Busan, Korea

Since 1975

Hyundai Ship Engineering

Core Business Areas

Shipbuilding & Marine Equipment

Hyundai Ship Engineering provide vessel design, construction, and model development based on extensive experience across various vessel types, including special-purpose vessels, leisure boats, and fishing vessels, as well as expertise in hull materials such as FRP, aluminum, and HDPE. We continue to grow by expanding its capabilities into the development and manufacturing of marine equipment. With its strong technological foundation, we are committed to delivering high-quality vessels and superior value to its customers.



Business Areas

Shipbuilding



Key Technologies



Major Clients



www.hdship-eng.com

hse-general@hdship-eng.com

+82-52-240-3504

272-12, Dangwol-ro, Onsan-eup, Ulju-gun, Ulsan,
Korea

**Semiconductor
·Energy**

HLB InnoVation

HLB Solution

HLB Energy

Since 1978

HLB InnoVation

Core Business Areas

Semiconductor Leadframe/ Bio

Since its establishment in 1978, it has grown into a global company providing total solutions in the semiconductor components sector, centering on lead frames. With a commitment to customer-centric management and cutting-edge technology, it has established itself as a leading company in the semiconductor components industry and continues to achieve sustainable growth through innovative technology development in the biotech sectors.

www.hlbinnovation.com


hlbinno_admin@hlbinno.com

+82-31-522-3700

16, Barangongdan-ro 4-gil, Hyangnam-eup,
Hwaseong-si, Gyeonggi-do, Korea



Business Areas / Major Clients




POWER MODULE

A lead frame for Smart/Intelligent Power-modules used in power conversion inverters for electric vehicles, home appliances, and other power semiconductor applications.



PRE-MOLD

A pre-molded lead frame primarily used for MEMS sensors in applications like automobiles and medical devices, particularly for image/pressure sensors. It's a high-value-added component.




CONTACT PIN

We produce and supply precision contact pins that are used in Burn-In test sockets for testing memory and non-memory semiconductor devices.



LEAD FRAME

We manufacture and supply various lead frames, such as IC and Discrete Power-TR, using our proprietary progressive precision molds.



Biotechnology

- Development of cell and gene therapy against solid and blood cancer.
- Coordinate cell and gene therapy development within the family company.
- Business development for commercializing cell and gene therapy.

Since 1998

HLB Solution

Core Business Areas

ESCO Project, Renewable Energy

Since its establishment in 1998, we have leveraged our accumulated experience and technical expertise to excel in the environmental and renewable energy sectors. We are committed to maximizing value for businesses and customers through process improvement, system optimization, robust construction, and ongoing research and development efforts.

www.hlb-ls.com

hlbls@hlb-ls.com

+82-2-2627-6700

8F, 51-9, Dongtancheomdansaneop 1-ro,
Hwaseong-si, Gyeonggi-do, Korea





Business Areas

ESCO Business (Energy Service Company)



The company participates in energy-saving facility replacement projects, providing technology and funds for energy diagnosis, facility replacement, and follow-up management. It is repaying investment costs with reduced energy costs achieved by replacing and enhancing existing facilities.

Renewable Energy Business



Renewable energy is one of the new growth engines serving as a fundamental solution to the depletion of fossil energy and environmental problems. The company is leading the market by planning one-stop services ranging from manufacturing, selling, and construction of fast chargers as a bridgehead for slow charging subsidies by entering the domestic electric vehicle charger business as well as solar and waste heat generation.

Business Performance



Dryer Waste Heat Recovery
Energy Business

OCI



Renewable Energy

Solar Power Generation(RE100)



Dryer Waste Heat Recovery
Energy Business

Electricity Supply Optimization



Renewable Energy

Solar Power Generation(PPA)

Since 1997

HLB Energy

Core Business Areas

Energy Resource Recovery

Since its establishment in 1997, HLB Energy has been striving for a pleasant living environment in Busan and other major cities as a resource recovery facility that incinerates waste through high-temperature combustion and reuses the energy produced. The company focuses on environmental conservation and recovery of energy resources through high-tech air pollution prevention facilities.



Business Areas



Waste Incineration

HLB Energy has a stoker-type incineration facility with a capacity to handle 90 tons per day, and a storage facility capable of storing 1,446 tons of industrial waste and 282 tons of designated waste. The company is contributing to creating a sustainable environment while complying with the government environmental standards.



Incineration Heat & Energy Supply

The company supplies the high-pressure steam generated by waste incineration to other companies, thereby maximizing its profits and reducing carbon emission by reusing the heat energy.



Waste collection and transportation

We provide a service that directly collects waste generated by waste discharging companies using vehicles that are suitable for the characteristics of the waste and transports it to the business site.

Major Clients



www.hlbenergy.com

im97@hlbenergy.co.kr

+82-51-266-6701

80, Gamcheonhang-ro 291beon-gil, Saha-gu, Busan, Korea

Lifestyle

HLB Global

HLB F&B

HLB Life & Healthcare

Freshico

Since 1963

HLB Global

Core Business Areas

Media Commerce · Retail

Since its establishment in 1963, HLB Global has grown into Asia's largest coal development company and was listed on the Korea Exchange in 1990. In 2023, it expanded into the media commerce business, diversifying its business areas and continuing its sustainable growth.

www.hlbglobal.co.kr

hlbglobal@hlbglobal.co.kr

+82-2-6952-0622



2F, The H Tower, 662, Nonhyeon-ro, Gangnam-gu,
Seoul, Korea



Business Areas

We aim to enhance everyday life by sourcing competitive products worldwide through our global network, and delivering new value to consumers. Building on our media commerce business, we manage a diverse range of brands in car accessories, perfumes, massagers, and household goods. Recently, we've expanded into the retail sector, partnering with major domestic distributors to broaden our business reach.

Major Brand





HLB Life & Healthcare

Since 2008

HLB Life & Healthcare

Core Business Areas

Vegan, Clean Beauty, Functional, and Color Cosmetics

HLB Life & Healthcare is a total beauty solution company that pursues healthy beauty. With distinctive brands such as ELISHACOY, a vegan clean beauty brand; TETRAFORCE, a professional trouble-care line; and MIIN SILOK, a premium fusion of tradition and science, we deliver differentiated skincare solutions.

In 2025, our subsidiary JHCOSLAB launched the artist-collaboration makeup brand #HANHYUNJAE, completing a full beauty lineup from skincare to makeup.

Now exporting to over 20 countries worldwide, we continue to grow as a leading force in the global K-beauty market.

www.hlbh.com
www.hhjbeauty.com

help@hlbh.com
+82-2-1544-7414

2F, The H Tower, 662, Nonhyeon-ro, Gangnam-gu,
Seoul, Korea



Business Areas



ELISHACOY

A vegan-oriented clean beauty brand that provides comfort and safety to the skin with a clean formula containing only the essential natural ingredients.



MIIN SILOK

A high-performance premium skincare brand that effectively addresses skin concerns through the fusion of local ingredients and advanced modern science.



TETRAFORCE

A professional trouble-care brand that analyzes the root causes of skin concerns and combines safe, nature-derived ingredients with scientific formulations for effective soothing care.



#HANHYUNJAE

A color makeup brand that captures the techniques and formulas verified by professional artists on-site, delivering flawless perfection without compromise.

Since 2017

HLB F&B

Core Business Areas

Han River Multipurpose Complex

HLB F&B provides customers with a unique experience through differentiated value. Located by the Han River, The River is a multipurpose complex that conveys the beauty of the Han River and enriches customers' lifestyles with a variety of offerings, including gourmet cuisine, yachting, and performances.

www.theriver.kr

fnb-inquiry@hlbfnb.com

+82-2-595-6640~3

2085-96, Olympic-daero, Yongsan-gu, Seoul, Korea



Business Areas

Convention Hall — Meetings & Events



NOCT — Wine & Jazz



MELT — Contemporary Bar



Le Da — Korean French Dining



Since 2013

Freshico

Core Business Areas

Kombucha, Jam/Syrup

FRESHICO INC. is a food and beverage company specializing in the development and production of innovative fermented products that promote Health & Well-being, achieving stable growth as a B2B manufacturer of fermented dairy products, fruit jams, and syrups.

As Asia's largest kombucha production facility, we lead the domestic market with antioxidant-rich organic green and black tea kombucha under the "I'm Alive Kombucha" brand, offering ODM/OEM services and exporting globally through patented fermentation technology and Halal certification.

www.freshico.co.kr

imalive@freshico.co.kr

070-4827-1182

457-30, Maejukheon-ro, Eunjin-myeon, Nonsan-si,
Chungcheongnam-do, Korea



Business Areas



I'm alive Kombucha


"I'm Alive Kombucha" has 506 hours of meticulous care infused into every bottle. Committed to delivering authentic kombucha, we use only the finest ingredients and a carefully crafted development process. Our unwavering commitment to quality reflects our passion for detail, ensuring that every bottle embodies our core beliefs. We let our dedication and time-tested process speak for themselves in each product we offer.



Jam/Syrup

Freshico's Jam and Syrup division has tirelessly researched and developed both dairy and non-dairy jams/syrups in our quest to establish our own distinctive taste and create a standalone brand. For a lengthy span of 38 years, we've built a B2B business based on trust, collaborating as a strategic partner with major food corporations. Recently, we have set up a small packaging line and are expanding into B2C businesses, focusing on beverage bases, smoothies, soft drinks, ripple jams, and

MAJOR CLIENTS



Investment

HLB Investment

Since 2021

HLB Investment

Core Business Areas

Venture Capital Investment, M&A / Investment Advisory

Established in May 2021, HLB Investment is a venture capital firm that supports the growth of promising companies in innovative sectors such as biotechnology, health-care, and beauty through investments and strategic advisory services.

In addition, the firm provides advisory services in M&A, equity divestments, and corporate finance, serving as a trusted strategic partner underpinned by strong investor confidence.

www.hlbkorea.com/group/finance

hi@hlbinvestment.co.kr

+82-2-539-4456

6th Floor, Jangppeol Building, 5 Nonhyeon-ro 128-gil
Gangnam-gu, Seoul, Korea



Business Areas



Venture Capital

Transformative innovation requires time, patience, and bold vision. HLB Investment stands as a committed partner to portfolio companies, accompanying them on their journey to success.



Corporate Investment Advisory

We serve as a trusted partner providing comprehensive advisory services across corporate transactions — encompassing M&A, equity acquisitions, venture investments, and post-merger integration (PMI) strategies — from deal execution through post-investment management.

Our M&A track record includes 6 private and 6 publicly listed companies.



Private Equity

We seek to broaden our presence in institutional private equity through the establishment of private collective investment vehicles, acting as General Partner (GP) to enhance investor value and long-term returns.



Mezzanine Investments

In compliance with the HLB Group's Code of Ethics, we build a diversified mezzanine investment portfolio — including convertible bonds (CB), bonds with warrants (BW), and exchangeable bonds (EB) — focusing on financially sound companies.

HUMAN LIFE BETTER

HLB Group

CONTACT

Bio · Pharmaceutical

Since 1975

HLB

Seoul Office - (06105) 6F, The H Tower, 662,
Nonhyeon-ro Gangnam-gu, Seoul,
Korea

T +82- 2-3453-1975 **F** +82- 70-4757-4757
H www.hlb-group.com
E hlb@hlb-group.com

Since 2008

HLB Healthcare Div.

HQ - (30068) 10-5, Myeonghaksandanseo-ro,
Yeon-dong-myeon, Sejong, Korea

T +82- 44-862-9134 **F** +82- 44-862-9135
H www.hlbhc.com
E hlbhc@hlbbio.co.kr

Since 1988

HLB Life Science

HQ - (18469) 8F, 51-9, Dongtancheomdansaneop
1-ro, Hwaseong-si, Gyeonggi-do, Korea

T +82- 2-2627-6700 **F** +82- 2-2627-6720
H www.hlh.com
E hlbhc@hlbhc.co.kr

Seoul Office - (06105) 5F, The H Tower, 662,
Nonhyeon-ro, Gangnam-gu,
Seoul, Korea

T +82- 2-2627-6700 **F** +82- 2-2627-6703
H www.hlb-ls.com
E hlb-ls@hlb-ls.com

Since 2009

HLB Life Science Medicare Div.

HQ - (17551) 104, Yongmeori-gil, Gongdo-eup,
Anseong-si, Gyeonggi-do, Korea

T +82- 31-658-8460 **F** +82- 31-688-0509
H www.hlb-lsmc.com
E info@hlb-ls.com

1nd Factory - (17551) 104, Yongmeorikeun-gil,
Gongdo-eup, Anseong-si,
Gyeonggi-do, Korea

Jinwi Office - (17708) 15-10 Jinwi 2-Sandan-ro,
Jinwi-myeon, Pyeongtaek-si,
Gyeonggi-do, Korea

T +82- 70-8672-5631

Since 2000

HLB Life Science Medical Devices Div.

HQ - (31244) 20, Seongsimwon-gil, Cheonan-si,
Chungcheongnam-do, Korea

Cheonan Factory - (31244) 20, Seongsimwon-gil,
Cheonan-si,
Chungcheongnam-do, Korea

T +82- 41-554-6181 **F** +82- 41-554-7178
H www.hlh.com
E hlbhc@hlbhc.co.kr

2nd Factory - (17551) 122-39, Gieopdanji-ro,
Gongdo-eup, Anseong-si,
Gyeonggi-do, Korea

T +82- 31-658-8460 **F** +82- 31-688-0509
E info@hlb-ls.com

Since 1998

HLB Pharmaceutical

HQ - (12244) 27, Gyeonggang-ro, Namyangju-si,
Gyeonggi-do

T +82- 31-557-0001 **F** +82- 31-557-6622
H www.hlbpharma.co.kr
E hlbpharma@hlbpharma.co.kr

Seoul Office - (05835) 9F, 67, Jeongui-ro, Songpa-gu,
Korea

T +82- 2-411-1500 **F** +82- 2-411-1590

Hyangnam plant - (18622) 35, Jeyakgongdan 2-gil,
Hyangnam-eup, Hwaseong-si,
Korea

T +82- 31-8059-8231

R&D Center (Dongtan) - (18469) 8F, 51-9,
Dongtancheomdansaneop
1-ro, Hwaseong-si, Korea

T +82- 31-8077-2453

R&D Center (Gunpo) - (15847) 1405, 38, Gongdan-ro
140beon-gil, Gunpo-si, Korea

T +82- 31-8068-8660

Since 2000

HLB Therapeutics

Seoul Office - (06105) 3F, The H Tower, 662,
Nonhyeon-ro, Gangnam-gu,
Seoul, Korea

T +82- 31-786-7800 **F** +82- 31-786-7801
H www.hlbtherapeutics.co.kr
E contact-hlbtr@hlbtherapeutics.com

Since 2012

HLB bioStep

HQ - (22014) 38, Academy-ro 79beon-gil,
Yeonsu-gu, Incheon, Korea

T +82- 32-833-8899 **F** +82- 507-0322-9594
H www.hlbbiostep.com
E ask@hlbbiostep.com

Since 2001

HLB Panagene

HQ - (34027) 54, Techno 10-ro, Yuseong-gu, Daejeon,
Korea

T +82- 42-861-9295 **F** +82- 42-861-9297
H www.hlbpanagene.com
E info@hlbpanagene.com

Since 2009

HLB Cell

HQ - (18469) 8F, 51-9, Dongtancheomdansaneop 1-ro, Dongtan-gu, Hwaseong-si, Gyeonggi-do, Korea

T +82-31-372-8578 **F** +82-31-374-8579

H www.hlbcell.co.kr

E hlbcell@hlbcell.co.kr

Since 2009

HLB bioCode

HQ - (16521) 155, Maeyoung-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea

T +82-31-278-5361 **F** +82-31-211-7845

H www.hlbbiocode.com

E bd@hlbbiocode.com

Since 2021

HLB LifeCare

HQ - (06226) 1F, 8, Yeoksam-ro 38-gil Gangnam-gu, Seoul, Korea

T +82-2-555-0128

H www.hblifecare.co.kr

E hlblifecare@hblifecare.com

Since 1998

HLB PEP

HQ - (61008) 206, Pilot Plant, Gwangju Technopark, Cheomdan Gwagi-ro 333, Buk-gu, Gwangju, Korea

T +82-62-714-1166

H www.hlbpep.co.kr

E order@hlbpep.co.kr

Osong GMP Plant - (28161) 773, Jeongjungyeonje-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Korea

Since 2000

HLB Genex

HQ - (34014) 65 Techno 1-ro, Yuseong-gu, Daejeon, Korea

T +82-42-862-4483

F +82-42-862-4484

H www.hlbgenex.com

E info@hlbgenex.com

Since 2021

HLB NeuroTobe

HQ - (34051) 193, munji-ro, Yuseong-gu Daejeon, Korea

T +82-42-862-9745

H www.hlbneurotobe.com

E hlbneurotobe@hlbneurotobe.com

Since 1991

Shinhwa Advance

HQ - 10, Seonyu-ro 9-gil, Yeongdeungpo-gu, Seoul Korea (215,216)

T +82-2-834-7971~3

H www.shinhwaadvance.kr

E shinhwa@sh-adv.co.kr

Warehouse - (07295) 60, Mullaero 20-gil, Yeongdeungpo-gu, Seoul, Korea (201,202,209)

T +82-2-834-7975

Since 2017

BioSquare

HQ - (18449) 15, Samsung 1-ro 4-gil, Hwaseong-si, Gyeonggi-do, Korea

T +82-31-8043-5293

H www.bio-square.com

E sales@bio-square.com

Since 2011

tiniko

HQ - (28164) 163, Osongsangmyeong 12-ro, Cheongju, Korea

T +82-70-7702-8727

H www.tiniko.co.kr

E Ji-hoon.kang@tiniko.co.kr

Since 2005

Elevar Therapeutics

HQ - (07024) One Bridge Plaza North Suite 850 Fort Lee, NJ U.S.A.

T +1-801-303-7440 **F** +1-801-303-7455

H www.elevartherapeutics.com

E info@elevartherapeutics.com

SF Office - (94080) 400 Oyster Point Blvd, Suite 214, San Francisco, CA, USA

Since 2005

Immunomic Therapeutics

HQ - (20850) 15010 Broschart Road Suite 250 Rockville, MD, USA

T +1-301-968-3501

H www.immunomix.com

E info@immunomix.com

Since 2020

Verismo Therapeutics

HQ - (19104) 3675 Market Street, Suite 200 Philadelphia, PA, USA

T +1-267-244-8115

H www.verismotheapeutics.com

E info@verismotheapeutics.com

Marine Business

Since 1975

HLB ENG

HQ - (45011) 216-53, Dangwo-ro, Onsan-eup, Ulju-gun, Ulsan, Korea

T +82 - 52 - 240 - 3500 **F** +82 - 52 - 237 - 4855

H www.hlb-eng.com

E techsales@hlb-eng.com

2nd factory - (44988) 243-22, Cheoyongsaneop-ro Ulsan, Korea

Since 1992

HLB Ocean Tech

HQ - (50859) 135-56, Jinsan-daero, Jinyeong-eup, Gimhae-si, Gyeongsangnam-do, Korea

T +82 - 55 - 720 - 1021/22/02 **F** +82 - 55 - 345 - 2136

H www.hlboceantech.com

E marketing@hlboceantech.com

Since 2009

HLB Networks

HQ - (45011) 216-53, Dangwo-ro, Onsan-eup, Ulju-gun, Ulsan, Korea

T +82 - 52 - 240 - 3529 **F** +82 - 52 - 237 - 4854

H www.hlbnetworks.com

E service@hdboat.com

Singapore Office - (079903) 10 Anson Road, #36-12 International Plaza

T +65 - 6493 - 6923~4 **F** +65 - 6493 - 6925

Shanghai Office - (201210) Room1107, Building1, No.2277, Zuchongjiang Hi-tech Park

T +86 - 21 - 5079 - 3528 **F** +86 - 21 - 5079 - 3520

Since 2008

Hyundai Yachts

HQ - (45011) 272-12, Dangwo-ro, Onsan-eup, Ulju-gun, Ulsan, Korea

T +82 - 2 - 561 - 1975 **F** +82 - 2 - 536 - 1978

Wangsan Business Place - (22383) A-1, 1F, 143, Wangsanmarina-gil, Jung-gu, Incheon, Korea, 1F, A-1

T +82 - 32 - 710 - 6975 **F** +82 - 32 - 710 - 6978

Seoul Business Place - (04428) 2085-96, Olympic-daero, Yongsan-gu, Seoul, Korea

T +82 - 2 - 536 - 1976 **F** +82 - 2 - 536 - 1978

H www.hdyachts.com | www.hdyachtclub.com

E info@hdyachts.com

Since 2014

Penguin Ocean Leisure

HQ - (45011) 272-12, Dangwo-ro, Onsan-eup, Ulju-gun, Ulsan, Korea

T +82 - 52 - 239 - 5225 **F** +82 - 52 - 237 - 4774

H www.tourwithpenguin.com

E inquiry@penguinol.com

Since 2017

DAEHAE Ship Engineering

HQ - (48059) Rm.1012-1014, 99, Centum dong-ro, Haeundae-gu, Busan, Korea

T +82 - 70 - 4416 - 0801

H www.daehae.com

E shipdh@daehae.com

Since 1975

Hyundai Ship Engineering

HQ - (45011) 272-12, Dangwo-ro, Onsan-eup, Ulju-gun, Ulsan, Korea

T +82 - 52 - 240 - 3504

H www.hdship-eng.com

E hse-general@hdship-eng.com

Semiconductor·Energy

Since 1978

HLB InnoVation

HQ - (18623) 16, Barangongdan-ro 4-gil,
Hyangnam-eup, Hwaseong-si,
Gyeonggi-do, Korea

T +82 - 31 - 522 - 3700 **F** +82 - 31 - 522 - 3716
H www.hlbinnno.com
E hlbinnno_admin@hlbinno.com

Since 1998

HLB Solution

HQ - (18469) 8F, 51-9,
Dongtan cheomdan saneop 1-ro,
Hwaseong-si, Gyeonggi-do, Korea

T +82 - 2 - 2627 - 6700 **F** +82 - 2 - 2627 - 6702
H www.hlb-ls.com
E hlb-ls@hlb-ls.com

Since 1997

HLB Energy

HQ - (49454) 80, Gamcheonhang-ro 291beon-gil,
Saha-gu, Busan, Korea

T +82 - 51 - 266 - 6701 **F** +82 - 51 - 266 - 6702
H www.hlbenergy.com
E im97@hlbenergy.co.kr

Lifestyle

Since 1963

HLB Global

HQ - (26150) 1F 101, 3583-1, Sogeumgang-ro,
Sabuk-eup, Jeongseon-gun, Gangwon-do,
Korea

T +82 - 2 - 6925 - 4450 **F** +82 - 2 - 6925 - 4449

Seoul Office - (06105) 2F, The H Tower, 662,
Nonhyeon-ro, Gangnam-gu, Seoul,
Korea

T +82 - 2 - 6952 - 0622 **F** +82 - 2 - 6952 - 0633
H www.hlbglobal.co.kr
E hlbglobal@hlbglobal.co.kr

Seoul Branch Office - (06193) 7F, 420, Teheran-ro,
Gangnam-gu, Seoul, Korea

T +82 - 70 - 8858 - 3439

Since 2008

HLB Life&Healthcare

HQ - (06105) 6F, The H Tower, 662, Nonhyeon-ro,
Gangnam-gu, Seoul, Korea

T +82 - 2 - 1544 - 7414
H www.hlb-lnh.com | www.hhjbeauty.com
E help@hlblnh.com

Since 2017

HLB F&B

HQ - (04428) 2085-96, Olympic-daero,
Yongsan-gu, Seoul, Korea

T +82 - 2 - 595 - 6640~3
H www.theriver.kr
E fnb-inquiry@hlbfnb.com

Since 2013

Freshico

HQ - (33004) 457-30, Maejukheon-ro, Nonsan,
Korea

T +82 - 41 - 742 - 8589 **F** +82 - 41 - 742 - 8590

Pangyo Office - (13488) 5F, 331, Pangyo-ro,
Bundang-gu, Seongnam-si,
Gyeonggi-do, Korea

T +82 - 31 - 698 - 2770 **F** +82 - 31 - 698 - 2771

Iksan Business Place - (54576) 5007-2, Gwang-am-ri,
Wanggung-myeon, Iksan-si,
Jeollabuk-do, Korea

T +82 - 63 - 836 - 0992 **F** +82 - 63 - 836 - 0993
H www.freshico.co.kr
E imative@freshico.co.kr

Investment

Since 2021

HLB Investment

HQ - (06104) 6th Floor, Jangppeol Building,
5 Nonhyeon-ro 128-gil, Gangnam-gu, Seoul,
Korea

T +82 - 2 - 539 - 4456 **F** +82 - 2 - 539 - 4457
E hi@hlbinvestment.co.kr



Blog



YouTube

